MedTrace Logo

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

NCT03732846 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2018-11-07

No results posted yet for this study

Summary

Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer

Conditions

  • Recurrent Small Cell Lung Cancer

Interventions

DRUG

Anlotinib

Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Jian Fang · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2020-05-01
Completion
2020-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03732846 on ClinicalTrials.gov